BODI Bodisen

RNS Number:2738T
Bodisen Biotech Inc
20 March 2007

BODISEN BIOTECH ANTICIPATES NOTICE OF DELISTING FROM THE AMEX, ANNOUNCES THAT IT
  WILL DELAY THE FILING OF ITS ANNUAL REPORT ON FORM 10-K AND PROVIDES UPDATED
                     INFORMATION REGARDING STOCK OWNERSHIP



Shaanxi, China - March 20, 2007 - Bodisen Biotech, Inc. (the "Company") (AMEX:
BBC, London AIM:BODI, website: www.bodisen.com) today is providing information
regarding the Company's anticipated delisting from the American Stock Exchange
(the "Amex"), the Company's delayed filing of its Annual Report on Form 10-K for
the fiscal year ended December 21, 2006, information regarding a potential
Company liability and updated information regarding the share ownership of Qiong
Wang and Bo Chen, the company's prior and current chief executive officers.



Bodisen Anticipates Notice of Delisting

            As previously disclosed, on November 6, 2006 the Company received
notice from the Amex indicating that the Company was below certain of the
Exchange's continued listing standards, specifically alleging that the Company
had failed to comply with Sections 132(a), 132(e) and 403 of the Amex Company
Guide.  The Company was afforded the opportunity to submit a plan of compliance
to the Amex.  On November 21, 2006, the Company timely submitted such a plan to
the Amex, and the Company provided the Amex with subsequent updates.  On January
4, 2007, the Company received a letter from the Amex indicating that the Amex
determined that the Company had made a reasonable demonstration of its ability
to regain compliance with the continued listing standards by the end of the plan
period.  The Amex determined that the plan period will end no later than the
timely filing of the Company's Form 10-K for the period ended December 31, 2006,
or April 17, 2007.  Accordingly, the Company's securities continued to be listed
on the Amex during this period pursuant to an extension.

             Under the specific terms of the plan, the Company was required to
provide certain information to the Amex through periodic updates.  The Company
has been unable to provide all such definitive information to the Amex within
the applicable time period.  Accordingly, the Company expects to soon receive
formal notice from the Amex indicating the Amex's intent to strike the Company's
common stock from listing on the Amex by filing a delisting application with the
Securities and Exchange Commission.  The Company will report the details of such
notice if and when it is received.


            The Company's failure to file its Annual Report on Form 10-K with
the Securities and Exchange Commission when due could serve as an additional
basis for Amex to commence delisting proceedings.  As discussed further below,
the Company has delayed the filing of its Annual Report on Form 10-K for the
fiscal year ended December 31, 2006.



Bodisen Becomes an Accelerated Filer



            The Company has determined that it ceased being a small business
issuer in 2006, and under applicable Securities and Exchange Commission
regulations, is deemed an accelerated filer.  Accordingly, the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2006 became due on
March 16, 2007.



Bodisen Delays Filing Annual Report on Form 10-K



            The Company intends to delay filing its Annual Report on Form 10-K
for the fiscal year ended December 31, 2006.  Accordingly, as of 5:31 p.m.
Eastern time on March 16, 2007, Bodisen no longer met the "current public
information" requirements of subsection (c) of Rule 144 under the Securities Act
of 1933, as amended.  The Company is working to complete its Annual Report as
soon as possible, but cannot at this time predict when it will file the Annual
Report for the fiscal year ended December 31, 2006.



Bodisen Updates Information Regarding Stock Ownership

            As part of its previously announced internal review, the Company is
providing updated information regarding the share ownership of Qiong Wang and Bo
Chen, its prior and current chief executive officers, as well as information
regarding claims that third parties may have that they are entitled to stock in
the Company.  The Company has not determined whether or not the updated
information impacts the Company's capitalization or creates a previously
unstated Company liability.



            In September 2005, Qiong Wang and Bo Chen made stock transfers to
individuals identified as their children.   The Company also understands that
the children made substantial stock transfers shortly thereafter to persons
residing in the People's Republic of China on whose behalf the shares were held
by Ms. Wang, Mr. Chen and the children.



            The Company understands that some or all of the 19 stockholders of
Bodisen International, Inc. (which, prior to the "reverse merger", was the
parent of what now is the Company's principal operating subsidiary) who received
stock in the "reverse merger" held at least a portion of such shares on behalf
of additional persons residing in China, with respect to which transfers have
not yet been made.  The exact nature and extent of these interests are not yet
known, including whether they support claims against individual stockholders or,
in contrast, claims against the Company.  As a result, at this time, the Company
cannot eliminate the possibility that, to the extent such interests exist and
support claims against the Company, they would constitute a material liability
or materially impact the capitalization of the Company.



            As a result of the reverse merger and after giving effect to the
3-for-1 stock dividend paid in 2004, these 19 stockholders originally held of
record 12,000,000 shares of the Company's common stock, of which Ms. Wang was
the record holder of 3,748,780 shares and Mr. Chen was the record holder of
3,584,096 shares.  According to the records of the Company's transfer agent,
Qiong Wang currently is record holder of 720,000 shares of the Company's common
stock and Bo Chen currently is record holder of 690,000 shares of the Company's
common stock.  According to the records of the Company's transfer agent, the
children of Qiong Wang and Bo Chen currently together hold 2,639 shares.



            The Company intends to provide additional information and make
appropriate SEC filings regarding the equity interests and the holdings of Qiong
Wang and Bo Chen and such third party claims once the Company and its advisors
complete their review of the Company's internal records and any relevant
documents.





About Bodisen Biotech, Inc.



Bodisen Biotech Inc. is a leading manufacturer of liquid and organic compound
fertilizers, pesticides, insecticides and agricultural raw materials certified
by the Petroleum Chemical Industry Administrative office of China (Chemical
Petroleum Production Administrative Bureau), Shaanxi provincial government and
Chinese government. The Company is headquartered in Shaanxi province and is a
Delaware corporation. The Company's environmentally friendly "green" products
have been proven to improve soil and plant quality, and increase crop yields.



Safe Harbor Statement



This press release may contain forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These statements are based on the current expectations or beliefs of
Bodisen Biotech, Inc. management and are subject to a number of factors and
uncertainties, and the outcome of events may differ materially from those
described in the forward-looking statements, including but not limited to the
Company's ability to file its Annual Report on Form 10-K for the fiscal year
ended December 31, 2006.

Investor Relations:
info@bodisen.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCJMMRTMMITMLR

Bodisen Biotech (LSE:BODI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Bodisen Biotech (LSE:BODI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024